 |
July 1, 2008 : |
Intellectual Property Report was updated |
|
May 26, 2008 : |
Medical Use Patent for the Combination Use of HGF and PGIS
Granted in Europe − Covering Angiogenic Therapy − |
|
May 15, 2008 : |
New Medical-Use Patent for HGF Gene Granted in Europe
- Covering Cardiomyopathy - |
|
April 14, 2008 : |
AnGes MG, Inc. Launched Naglazyme in Japan |
|
April 7, 2008 : |
Medical Use Patent on NF-κB Decoy-Oligo Granted in Europe - Covering Its Use for Atopic Dermatitis |
|
March 28, 2008 : |
AnGes MG, Inc. Receives Approval for Manufacturing and Marketing of Naglazyme |
|
February 25, 2008 : |
Status Updates of NDA application of Naglazyme for the Treatment of Mucopolysaccharidosis VI |
|
February 12, 2008 : |
Supplemental Announcement of Results of Phase II Clinical Trials of NF-κB Decoy Oligodeoxinucleotides on Atopic Dermatitis |
|
February 8, 2008 : |
Announcement of Results of Phase II Clinical Trials of NF-κB Decoy Oligodeoxynucleotide on Atopic Dermatitis |
|
November 15, 2007 : |
Announcement of a Contract Concluded by Three Companies on
R&D of “Drug-Eluting Balloon Catheter” for Prevention of
Vascular Restenosis |
|
November 15, 2007 : |
Announcement of Joint R&D Contract Termination between
Goodman Co., Ltd. and AnGes MG, Inc. |
|
November 13, 2007 : |
AnGes MG, Inc., Signs Licensing Deal with Meyer Pharmaceuticals, LLC - The Development and Marketing of NF-κB Decoy Oligo in North America and Europe- |
|
October 29, 2007 : |
Academic Release of Data from Phase III Clinical Trial of HGF Gene Therapy Conducted in Japan |
|
August 31, 2007 : |
A Research-and-Development Project of GenomIdea Inc.,
a Subsidiary of AnGes MG, Inc. is Granted Subsidy from New Energy and Industrial Technology Development Organization - Development of Cancer Therapeutic Agent Using HVJ-E Vector - |
|
August 29, 2007 : |
Basic Patent of HGF Gene Therapy is Granted in Korea |
|
August 13, 2007 : |
AnGes MG, Inc. Submits BLA for Naglazyme in Japan |
|
July 11, 2007 : |
Basic Patent for HVJ-E Granted in Japan: A Patent Covering HVJ-E Vector (Product Patent) |
|
July 9, 2007 : |
Completion of Targeted Number of Patient Enrollment in Phase II Clinical Trial of NF-κB Decoy Oligo for the Treatment of Atopic Dermatitis in Japan |
|
July 3, 2007 : |
Intellectual Property Report was updated |
|
June 20, 2007 : |
Announcement on Acquisition of First-Class Drug Marketing Business License |
|
June 14, 2007 : |
Announcement of Results of Phase III Clinical Trials
of HGF Gene Therapy in Japan |
|
June 7, 2007 : |
Announcement Regarding the Official Designation of Naglazyme as an Orphan Drug |
|
February 15, 2007 : |
Toyobo and GenomIdea Forms Business Alliance
- Product Launch of Master Cell Bank for Drug Manufacturing - |
|
February 7, 2007 : |
New Medical-Use Patent for HGF Gene Granted in Japan - Covering Intractable and Diabetes-related Peripheral Arterial Occlusive Diseases - |
|
January 22, 2007 : |
AnGes MG, Inc. Announces Marketing and Distribution Agreement with BioMarin Pharmaceutical Inc. for Naglazyme in Japan |
|
January 11, 2007 : |
The Clinical Trial of HGF Plasmid in Japan has Achieved Necessary
Number of Subject Enrollment for Efficacy Analysis |
|
January 10, 2007 : |
New Medical-Use Patent for HGF Gene Granted in Japan - Covering Cardiomyopathy - |
|
January 5, 2007 : |
Vical Initiates Pivotal Phase 3 Trial of Allovectin-7® as First-line Therapy for Metastatic Melanoma |
|
November 13, 2006 : |
Avontec (Germany) Starts Phase IIa Clinical Trials of AVT-01
- Obtaining Approval for Initiation of Clinical Trials in the Field of Asthma in Europe - |
|
October 31, 2006 : |
AnGes MG Launches Phase II Clinical Trials of NF-κB Decoy Oligo in the Treatment of Atopic Dermatitis in Japan |
|
October 18, 2006 : |
Efficacy of Drug Delivery System (DDS) Nanoparticles Supported Nucleic Acid
Medicine for Atopic Dermatitis, Developed by Hosokawa Powder Technology
Research Institute and AnGes MG, Inc. Confirmed in Animal Experiments |
|
September 7, 2006 : |
AnGes MG Submitted the Notification of the Clinical Trial Plan for NF-κB Decoy Oligo
- Phase II Clinical Trials of NF-κB Decoy Oligo for the Treatment of Atopic Dermatitis Commences - |
|
June 5, 2006 : |
AnGes MG, Inc. Announce their Policy for Future Development of HGF Gene Therapy |
|
June 5, 2006 : |
AnGes MG, Inc. Releases the Results of the US Phase II
Clinical Trial with HGF Gene Plasmid for PAD (Peripheral Arterial Disease) |
|
June 1, 2006 : |
Completion of Reexamination of the Basic US Patent on
NFκB Decoy Oligonucleotide
-Decision to Maintain Patent- |
|
May 30, 2006 : |
AnGes MG, Inc. and Vical Inc. Sign Collaborative R&D Agreement for Allovectin-7® as well as Equity Investment Agreement |
|
May 26, 2006 : |
Results of Phase I Clinical Trials of NFκB Decoy Oligo
in the Treatment of Atopic Dermatitis |
|
May 24, 2006 : |
A Japanese Medical-Use Patent is Granted for NFκB Decoy Oligonucleotide
-Covering Treatment for Atopic Dermatitis- |
|
May 23, 2006 : |
Intellectual Property Report was updated |
|
May 8, 2006 : |
Results of the US Phase I Clinical Trials with HGF Gene Plasmid for
Ischemic Heart Disease (IHD) |
|
April 3, 2006 : |
AnGes MG, Inc. Announces Newly Establishing a Position of CIPO
(Chief Intellectual Property Officer) |
|
February 22, 2006 : |
AnGes MG, Inc. Announced Preliminary Results of the US Phase II Clinical
Trial with HGF Gene Therapy for PAD (Peripheral Arterial Disease) |
|
February 3, 2006 : |
Termination of Joint Development with Seikagaku Corporation |
|
January 31, 2006 : |
Medical-Use Patent for HGF Gene Granted in U.S.
- Covering Cardiomyopathy - |
|
November 29, 2005 : |
AnGes Group Forms Business Alliance with FALCO biosystems |
|
November 22, 2005 : |
Completion of Trial Subject Enrollment for U.S. Phase I Clinical Trial of HGF Plasmid for Ischemic Heart Disease (IHD) |
|
October 11, 2005 : |
Osaka University, AOKI and AnGes MG Joint Development Project Launched
- Development of Fully Bioabsorbable Next-generation Magnesium Stent - |
|
October 4, 2005 : |
Medical -Use Patent for HGF (VEGF) Gene Granted in the U.S.
− Covering Cerebrovascular Disorders − |
|
October 3, 2005 : |
Hosokawa Powder Technology Research Institute
Succeeds in Encapsulating Nucleic Acid Drug Developed by AnGes MG
within Drug Delivery System (DDS) Nanoparticles
− Evaluation of “Nucleic Acid DDS Preparation” Technology
for Inflammatory Dermatoses Begins − |
|
September 26, 2005 : |
Domestic Clinical Trial for NFκB Decoy Oligo Launched
− Phase I Clinical Trial in Atopic Dermatitis Commences − |
|
August 15, 2005 : |
Basic Patent for HVJ-E Is Granted in the U.S. Covering HVJ-E As a Foreign Gene Transferring Vector
(Patent for material, usage/transfection method and preparation process of HVJ-E) |
|
August 10, 2005 : |
Avontec (Germany) and AnGes MG to form an Alliance
-- Obtained a license of STAT-1 Decoy Oligo in Asi -- |
|
August 10, 2005 : |
Nikko Principal Investments Japan Ltd and AnGes MG Inc to form an alliance in Pharma/Lifesciences area
~ An Alliance Fund has been jointly established, and the first investment just completed to a drug development company ~ |
|
August 1, 2005 : |
Consolidated Financial Report for the 6 months ended June 30, 2005 |
|
July 25, 2005 : |
Pharmaceuticals and Medical Devices Agency Completes Review of Initial IND for NFκB Decoy Oligo
- Phase I Clinical Trial in Atopic Dermatitis Underway - |
|
July 8, 2005 : |
AnGes MG Forms Business Alliance with Alfresa Pharma Corporation
- Joint Research on Atopic Dermatitis Therapeutic Medicine to Prepare for AnGes MG Establishing its own Sales Network - |
|
June 21, 2005 : |
Rush University Medical Center /USA and AnGes MG executes License Agreement
- AnGes obtains the exclusive right to develop and sell NFκB Decoy Oligonucleotide as a treatment for Disc Degeneration - |
|
June 13, 2005 : |
Basic patent of HGF gene therapy is granted in Europe
- Our foundation of HGF gene therapy international development is strengthened. -
|
|
June 8, 2005 : |
AnGes MG Starts to Explore Feasibility of a New DDS Drug with MedGel
- Toward Expanding the Application Range of NFκB Decoy Oligo - |
|
May 24, 2005 : |
Execution of License Agreement with Vical (USA) related to Non-viral Gene Delivery Technology
--Obtained an exclusive right for HGF gene’s delivery-- |
|
April 28, 2005 : |
GenomIdea Launches Service with Mitsubishi Space Software
- Drug Design Service for Next-Generation Nucleic Acid Medicine “siRNA” - |
|
April 27, 2005 : |
Completion of Trial Subject Enrollment for the US Phase II Clinical Trial of HGF Plasmid for Peripheral Arterial Disease (PAD) |
|
January 26, 2005 : |
Launch of Joint Research Project between the University of Tokyo Hospital and AnGes MG
--To develop cutting-edge clinical medicine, including genetic medication and cell remediation medicines-- |
|
January 24, 2005 : |
The Research-and-Development Type Venture Business Consortium That Includes AnGes MG, To Receive Research Grant From New Energy and Industrial Technology Development Organization
--Development of NFκB decoy oligo therapeutic agent for IBD-- |
|
December 9, 2004 : |
AnGes MG Selected by Pharmaceuticals and Medical Devices Agency for Research Grant
--Clinical trials are anticipated using NFκB decoy oligo therapeutic agent for atopic dermatitis-- |
|
November 24, 2004 : |
Phase I clinical trials of HGF plasmid for the treatment of Ischemic Heart Disease (IHD) underway in the United States
-- Clinical trials of HGF plasmid for both peripheral arterial disease (PAD) and IHD -- |
|
November 9, 2004 : |
AnGes MG Joins Hands with ImmunoFrontier
-- Transfer of Patent Rights for Cancer DNA Vaccine -- |
|
September 1,
2004 : |
Announcement:
Relocation of Headquarters and Research Center
-- Integration of Headquarters and Research Center
to Saito -- |
|
July 26, 2004
: |
GenomIdea's
Joint Development with Mitsubishi Space Software
Bears Fruit
-- Development of a New Drug Design System for the
Next-generation Nucleic acid Medicine "siRNA"
Completed -- |
|
July 12, 2004
: |
The
U.S. Food and Drug Administration (FDA) has given
the go-ahead for a clinical trial investigating
AnGes' HGF plasmid for the treatment of ischemic
heart disease (IHD). This U.S. study will be the
first clinical investigation of HGF plasmid for
IHD. |
|
June 30, 2004
: |
AnGes
MG to Join the University of Tokyo (Hospital) Project:"22nd
Century Medical Center" (tentative name)
-Establishes joint research program on forefront
clinical medicine, including development of genetic
medication and cell remediation medicines.- |
|
June 28, 2004
: |
Launch
of Shimadzu Corporation and AnGes MG Joint Research
Project
-To develop a new therapy for refractory dermatosis
with nucleic acid medicines administered via the
needleless pressure injector "Shima JET."
- |
|
June 7, 2004
: |
AnGes
MG Forms a Business Alliance with NeoChemir.
Expands treatments of ischemic diseases through
introduction of a new carbon dioxide generating
wound dressing material |
|
June 1, 2004 : |
The homepage was renewed. |
|
March 23, 2004
: |
AnGes
MG Seeks Faster New Drug Approval-Applications Via
Document Management System
- Infocom to be systems integrator for application
submission system - |
|
March 17, 2004 : |
AnGes
MG Expanding Its US Presence
- Licensing activities now in full-swing on the
bioventure-rich US West Coast - |
